<DOC>
	<DOCNO>NCT01617629</DOCNO>
	<brief_summary>The purpose trial ass safety profile Cvac epithelial ovarian cancer patient enrol Cvac clinical trial CAN-003 longer eligible study participation due disease progression .</brief_summary>
	<brief_title>Ovarian Cancer Vaccine Patients Who Have Progressed During CAN-003 Study</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Female patient ≥ 18 year old histologically confirm Stage III IV epithelial ovarian , primary peritoneal , fallopian tube cancer enrol CAN003 Able willing undergo MNC collection ( required patient available Cvac dos ) Were enrol CAN003 meet protocol criterion progressive disease Wish remain study , investigator 's judgment , potential benefit Cvac treatment outweighs risk Must nonpregnant , childbearing potential , must use adequate birth control ( hormonal barrier method birth control abstinence ) duration study 3 month study completion Able provide write informed consent White blood cell count ( WBC ) ≥ 3.0 K/μL , absolute neutrophil count ≥ 1.5 K/μL , hemoglobin ≥ 9.0 g/dL , platelet ≥100,000/mm3 Pregnant breastfeeding Other medical condition preclude study participation , opinion investigator Receiving treatment investigational product</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Cvac</keyword>
</DOC>